Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 28

PMID 35897789

Authors

Nami Yamashita

Donald Kufe

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options. TNBC progression is associated with expansion of cancer stem cells (CSCs). Few insights are available regarding druggable targets that drive the TNBC CSC state. This review summarizes the literature on TNBC CSCs and the compelling evidence that they are addicted to the MUC1-C transmembrane protein. In normal epithelia, MUC1-C is activated by loss of homeostasis and induces reversible wound-healing responses of inflammation and repair. However, in settings of chronic inflammation, MUC1-C promotes carcinogenesis. MUC1-C induces EMT, epigenetic reprogramming and chromatin remodeling in TNBC CSCs, which are dependent on MUC1-C for self-renewal and tumorigenicity. MUC1-C-induced lineage plasticity in TNBC CSCs confers DNA damage resistance and immune evasion by chronic activation of inflammatory pathways and global changes in chromatin architecture. Of therapeutic significance, an antibody generated against the MUC1-C extracellular domain has been advanced in a clinical trial of anti-MUC1-C CAR T cells and in IND-enabling studies for development as an antibody-drug conjugate (ADC). Agents targeting the MUC1-C cytoplasmic domain have also entered the clinic and are undergoing further development as candidates for advancing TNBC treatment. Eliminating TNBC CSCs will be necessary for curing this recalcitrant cancer and MUC1-C represents a promising druggable target for achieving that goal.

Citing Articles

The mechanism underlying metastasis in triple-negative breast cancer: focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs.

Chen Z, Zhao Y Front Pharmacol. 2025; 15:1437022.

PMID: 39881868 PMC: 11774878. DOI: 10.3389/fphar.2024.1437022.

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.

Research progress of MUC1 in genitourinary cancers.

Mao W, Zhang H, Wang K, Geng J, Wu J Cell Mol Biol Lett. 2024; 29(1):135.

PMID: 39491020 PMC: 11533421. DOI: 10.1186/s11658-024-00654-x.

A mini-review-cancer energy reprogramming on drug resistance and immune response.

Liu C, Yang L, Gao T, Yuan X, Bajinka O, Wang K Transl Oncol. 2024; 49:102099.

PMID: 39163759 PMC: 11380382. DOI: 10.1016/j.tranon.2024.102099.

MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.

Bhattacharya A, Wang K, Penailillo J, Chan C, Fushimi A, Yamashita N Oncogene. 2024; 43(28):2199-2214.

PMID: 38802648 PMC: 11226401. DOI: 10.1038/s41388-024-03068-3.

References

Habib J, OShaughnessy J . The hedgehog pathway in triple-negative breast cancer. Cancer Med. 2016; 5(10):2989-3006. PMC: 5083752. DOI: 10.1002/cam4.833. View

Kimura T, Finn O . MUC1 immunotherapy is here to stay. Expert Opin Biol Ther. 2012; 13(1):35-49. DOI: 10.1517/14712598.2012.725719. View

Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D . Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Mol Cancer Res. 2013; 11(7):714-23. PMC: 3720729. DOI: 10.1158/1541-7786.MCR-12-0668. View

Honeth G, Bendahl P, Ringner M, Saal L, Gruvberger-Saal S, Lovgren K . The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008; 10(3):R53. PMC: 2481503. DOI: 10.1186/bcr2108. View

Rajabi H, Hiraki M, Tagde A, Alam M, Bouillez A, Christensen C . MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep. 2017; 7(1):7481. PMC: 5547076. DOI: 10.1038/s41598-017-07850-0. View

Qureshi S, Chan N, George M, Ganesan S, Toppmeyer D, Omene C . Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker. Biomark Insights. 2022; 17:11772719221078774. PMC: 8874164. DOI: 10.1177/11772719221078774. View

Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C . MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. Cancer Res. 2019; 79(22):5711-5722. PMC: 6881519. DOI: 10.1158/0008-5472.CAN-19-1034. View

Mitchell P, Thatcher N, Socinski M, Wasilewska-Tesluk E, Horwood K, Szczesna A . Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015; 26(6):1134-1142. DOI: 10.1093/annonc/mdv104. View

Kufe D . Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009; 8(13):1197-203. PMC: 3035104. DOI: 10.4161/cbt.8.13.8844. View

10.

Kufe D . Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009; 9(12):874-85. PMC: 2951677. DOI: 10.1038/nrc2761. View

11.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J . A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Mol Med. 2019; 11(10):e9930. PMC: 6783652. DOI: 10.15252/emmm.201809930. View

12.

Raina D, Agarwal P, Lee J, Bharti A, McKnight C, Sharma P . Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156. PMC: 4534190. DOI: 10.1371/journal.pone.0135156. View

13.

Park S, Choi J, Nam J . Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678244. DOI: 10.3390/cancers11070965. View

14.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

15.

Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong K . Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res. 2014; 20(21):5423-34. PMC: 4219601. DOI: 10.1158/1078-0432.CCR-13-3168. View

16.

OConor C, Chen T, Gonzalez I, Cao D, Peng Y . Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker. Biomark Med. 2018; 12(7):813-820. DOI: 10.2217/bmm-2017-0398. View

17.

Kufe D . MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020; 41(9):1173-1183. PMC: 7513951. DOI: 10.1093/carcin/bgaa082. View

18.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C . Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2013; 33(26):3422-31. PMC: 3916940. DOI: 10.1038/onc.2013.308. View

19.

Huang L, Liao X, Beckett M, Li Y, Khanna K, Wang Z . MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation. Genes Cancer. 2010; 1(3):239-250. PMC: 2943399. DOI: 10.1177/1947601910368059. View

20.

Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi M . MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem. 2012; 287(13):10703-10713. PMC: 3322974. DOI: 10.1074/jbc.M111.323311. View